Ask AI
ProCE Banner Activity

Striving for Improvement in Australia: Takeaways From EACS 2025

Clinical Thought

Despite excellent efficacy of current antiretroviral therapy (ART) for HIV, there are still significant challenges in adherence, long term comorbidities, adverse effects and occasional regimen failure among people living in Australia. Learn how abstracts from the recent EACS 2025 meeting in Paris may inform future HIV clinical practice in Australia. 

Released: December 05, 2025

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from Gilead Sciences, Inc., Merck & Co., Inc., Rahway, NJ, USA, and ViiV Healthcare.

Gilead Sciences, Inc.

Merck & Co., Inc., Rahway, NJ, USA

ViiV Healthcare

Target Audience

This activity is intended for physicians, pharmacists, registered nurses, and other healthcare professionals who care for people living with or at risk of HIV infection.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Devise HIV management strategies based on the results of recent clinical studies of established antiretroviral agents

  • Appropriately apply and counsel patients regarding the clinical role(s) of new and investigational ART regimens and strategies

Disclosure

Primary Author

Sharon R. Lewin, AO, FRACP, PhD, FAAHMS, FAA: consultant/advisor/speaker: AbbVie, Esfam, Gilead, Merck, ViiV.